Metformin formulation
Pro Research Analysisby 
Searched over 200M research papers for "metformin formulation"
Extended Release and Sustained Release Metformin Formulations
Several studies have focused on developing extended-release (ER) and sustained-release (SR) formulations of metformin to improve patient compliance and reduce side effects. Extended-release oral suspensions using metformin hydrochloride pellets coated with ethylcellulose and suspended in a sugar-free syrup vehicle have shown promising results, with optimized batches releasing over 85% of the drug within 8 hours and following zero-order kinetics, which helps maintain steady drug levels in the body . Similarly, sustained-release matrix tablets prepared with blends of hydroxypropyl methylcellulose (HPMC) and polyvinyl pyrrolidone (PVP K30) have demonstrated the ability to prolong metformin release for 8–12 hours, potentially reducing dosing frequency and improving patient adherence .
Gastroretentive and In Situ Gel Formulations for Metformin
Gastroretentive in situ oral gels have been developed to further enhance metformin’s bioavailability and patient compliance. These gels, formulated with sodium alginate, calcium carbonate, and hydroxyethylcellulose, float in the stomach and release metformin slowly, meeting pharmacopeial standards for extended release. The systematic use of design of experiments (DoE) has enabled the optimization of these formulations for controlled drug release and favorable physicochemical properties .
Microparticulate and Nanoparticulate Metformin Delivery Systems
Microparticles and nanoparticles are being explored to address metformin’s low oral bioavailability and short half-life. Metformin-loaded poly(lactic acid) (PLA) microparticles have shown sustained-release characteristics in animal studies, with delayed peak concentration, longer mean residence time, and extended half-life compared to standard oral solutions . Similarly, metformin-loaded mucoadhesive microspheres and nanoparticles using Eudragit RSPO have demonstrated enhanced bioavailability, sustained drug release, and potential anticancer effects, with drug release primarily governed by non-Fickian diffusion . Reviews confirm that these advanced delivery systems can reduce dosing frequency, minimize gastrointestinal side effects, and may be useful for cancer therapy .
Alginate Bead and Niosome-Based Oral Formulations
Entrapping metformin-loaded niosomes or chitosomes in calcium alginate beads has been shown to significantly reduce drug release in the stomach and provide sustained release in the intestine. This approach improves the hypoglycemic effect and extends the duration of action, which could allow for lower doses and fewer side effects, ultimately enhancing patient compliance .
Transdermal and Topical Metformin Formulations
To avoid gastrointestinal side effects, transdermal and topical formulations of metformin are being developed. Liquid crystalline lipid particle (LCLP)-based transdermal gels have achieved high drug encapsulation, sustained release, and significant blood glucose reduction in diabetic rats, with no observed skin irritation or tissue damage . Ethosome-based topical gels have also shown high entrapment efficiency and improved skin permeation, with promising antitumor activity in animal models of skin cancer .
Conclusion
Metformin formulation research is rapidly evolving, with a variety of innovative delivery systems—such as extended-release suspensions, sustained-release tablets, gastroretentive gels, microparticles, nanoparticles, alginate beads, and transdermal gels—demonstrating improved drug release profiles, enhanced bioavailability, reduced side effects, and better patient compliance. These advances offer significant potential for optimizing metformin therapy in diabetes management and beyond Patil2024Suhel2022Kim2022+6 MORE.
Sources and full results
Most relevant research papers on this topic